z-logo
Premium
Role of leukotriene B4 in accelerated hyperlipidaemic renal injury
Author(s) -
DOI KENT,
HAMASAKI YOSHIFUMI,
NOIRI EISEI,
NOSAKA KAZUO,
SUZUKI TAKAKO,
TODA AKIKO,
SHIMIZU TAKAO,
FUJITA TOSHIRO,
NAKAO AKIHIDE
Publication year - 2011
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2010.01387.x
Subject(s) - medicine , leukotriene b4 , antagonist , endocrinology , kidney , excretion , leukotriene , inflammation , receptor , asthma
Aim:  Glomerular infiltration of macrophages is a characteristic alteration of renal pathology in hyperlipidaemic renal injury. Leukotriene B4 (LTB4) is a bioactive eicosanoid and macrophage and has two key enzymes for LTB4 synthesis, 5‐lipoxygenase and leukotriene A4 (LTA4) hydrolase. The purpose of this study was to evaluate the role of LTB4 in accelerated hyperlipidaemic renal injury. Methods:  To induce accelerated hyperlipidaemic renal injury, 8 week old male spontaneously hypercholesterolaemic (SHC) rats were fed with a high cholesterol diet for 6 weeks. LTA4 hydrolase activities in the kidney and urine LTB4 levels were examined. The effects of LTB4 antagonist (ONO‐4057) were also evaluated. Results:  Urinary protein and LTB4 excretion was increased by a high cholesterol diet for 6 weeks. The scores of glomerular foam cell accumulation and sclerosis, numbers of infiltrated macrophages in glomeruli and interstitial area, LTA4 hydrolase activity in renal cortex were higher in the high cholesterol diet group than the normal diet group. LTB4 antagonist treatment reduced urinary protein and LTA4 activity and attenuated renal pathological changes. Conclusion:  These results suggest that LTB4 directly contributes to accelerated hyperlipidaemic renal injury and the therapeutic potential of LTB4 antagonist for renal damage induced by hyperlipidaemia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here